Cabot (NYSE:CBT) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Cabot (NYSE:CBTFree Report) from a hold rating to a buy rating in a research report sent to investors on Sunday.

Several other analysts also recently commented on the company. Weiss Ratings restated a “hold (c)” rating on shares of Cabot in a research note on Tuesday, May 26th. UBS Group dropped their price target on Cabot from $97.00 to $92.00 and set a “neutral” rating on the stock in a research note on Wednesday. Mizuho increased their price target on Cabot from $80.00 to $90.00 and gave the stock a “neutral” rating in a report on Thursday, June 25th. JPMorgan Chase & Co. raised their price objective on Cabot from $70.00 to $78.00 and gave the company an “underweight” rating in a research note on Friday. Finally, Truist Financial set a $100.00 price objective on Cabot in a report on Wednesday. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Cabot presently has an average rating of “Hold” and a consensus price target of $89.00.

View Our Latest Report on CBT

Cabot Stock Performance

Shares of CBT stock opened at $87.69 on Friday. The firm has a 50 day moving average of $87.92 and a 200-day moving average of $79.93. The company has a market cap of $4.53 billion, a price-to-earnings ratio of 24.70, a price-to-earnings-growth ratio of 11.45 and a beta of 0.84. The company has a quick ratio of 0.97, a current ratio of 1.47 and a debt-to-equity ratio of 0.48. Cabot has a 52 week low of $58.33 and a 52 week high of $94.53.

Cabot (NYSE:CBTGet Free Report) last posted its quarterly earnings results on Monday, August 3rd. The specialty chemicals company reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.66 by $0.01. Cabot had a net margin of 5.23% and a return on equity of 20.29%. The business had revenue of $982.00 million during the quarter, compared to analysts’ expectations of $943.16 million. During the same period last year, the company posted $1.90 earnings per share. The business’s quarterly revenue was up 6.4% on a year-over-year basis. Cabot has set its FY 2026 guidance at 6.150-6.450 EPS. On average, equities analysts forecast that Cabot will post 6.32 earnings per share for the current year.

Cabot Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 28th will be given a $0.4725 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $1.89 annualized dividend and a yield of 2.2%. Cabot’s dividend payout ratio (DPR) is presently 53.24%.

Institutional Trading of Cabot

Several institutional investors and hedge funds have recently modified their holdings of the stock. NewEdge Advisors LLC boosted its position in shares of Cabot by 2,559.5% during the first quarter. NewEdge Advisors LLC now owns 984 shares of the specialty chemicals company’s stock valued at $82,000 after buying an additional 947 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Cabot by 32.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 442,646 shares of the specialty chemicals company’s stock valued at $36,802,000 after buying an additional 108,645 shares during the last quarter. Empowered Funds LLC lifted its stake in Cabot by 102.6% during the 1st quarter. Empowered Funds LLC now owns 28,162 shares of the specialty chemicals company’s stock valued at $2,341,000 after acquiring an additional 14,260 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Cabot by 3.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 122,022 shares of the specialty chemicals company’s stock valued at $10,145,000 after acquiring an additional 4,048 shares in the last quarter. Finally, Geneos Wealth Management Inc. boosted its holdings in Cabot by 409.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock worth $38,000 after acquiring an additional 364 shares during the last quarter. 93.18% of the stock is owned by hedge funds and other institutional investors.

Cabot Company Profile

(Get Free Report)

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.

See Also

Analyst Recommendations for Cabot (NYSE:CBT)

Receive News & Ratings for Cabot Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabot and related companies with MarketBeat.com's FREE daily email newsletter.